-

04:33:03 PM

Latest PGEN Stock Market News

PGEN - Precigen Inc

06/10/21 5:05 PM

Nasdaq : PGEN

Precigen ActoBio Announces Positive Topline Results from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes

Precigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a wholly-owned subsidiary of Precigen, Inc. (Nasdaq: PGEN), today announced positive topline results for the ongoing

RHEA-AI

neutral

06/10/21 4:05 PM

Nasdaq : PGEN

Precigen to Present at the JMP Securities Life Sciences Conference

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in

RHEA-AI

neutral

05/10/21 4:30 PM

Nasdaq : PGEN

Precigen Reports First Quarter 2021 Financial Results

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter 2021 financial results."In the first quarter of 2021, our

RHEA-AI

neutral

03/30/21 4:05 PM

Nasdaq : PGEN

Precigen Announces Departure of Chief Financial Officer

Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that by mutual agreement Rick Sterling is stepping down from his position as Chief

RHEA-AI

positive

03/23/21 8:05 AM

Nasdaq : PGEN

Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)

Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the first patient has been dosed in the Phase I study of PRGN-2012, a

RHEA-AI

positive

03/18/21 8:30 AM

Nasdaq : PGEN

Precigen Receives FDA Orphan Drug Designation for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)

Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation

RHEA-AI

very positive

03/01/21 4:05 PM

Nasdaq : PGEN

Precigen Reports Fourth Quarter and Full Year 2020 Financial Results

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced fourth quarter and full year 2020 financial results."2021 promises to

RHEA-AI

neutral

02/22/21 4:05 PM

Nasdaq : PGEN

Precigen to Announce Fourth Quarter and Full Year 2020 Financial Results on March 1st

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release fourth quarter and full year 2020 financial

RHEA-AI

neutral

02/04/21 4:05 PM

Nasdaq : PGEN

Precigen to Participate in Guggenheim Healthcare Talks Oncology Day

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a

RHEA-AI

positive

01/26/21 4:05 PM

Nasdaq : XON, PGEN

Precigen Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

Precigen, Inc. (Nasdaq: PGEN) announced today the closing of its previously announced underwritten public offering of common stock. Precigen sold 17,250,000 shares of its common stock at a public offering price of $7.50 per share, including the

RHEA-AI

neutral

PGEN Data

industryResearch and Development in Biotechnology
websiteprecigen.com
ceoHelen Sabzevari
security namePrecigen Inc
issue typecs
sectorProfessional, Scientific, and Technical Services
sic code8731
employees
tagsHealth Technology,Biotechnology
address20374 Seneca Meadows Parkway
address2
stateMaryland
cityGermantown
zip20876
countryUS
phone13015569900

PGEN Description:

Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The Company's technologies enable to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.